inhibitors (SC-TNFis) have transformed the management of inflammatory joint diseases such as rheumatoid arthritis (RA). The assessment of SC-TNFis persistence and its determinants is needed. Objectives: The objective of this study was to describe treatment persistence in real-world settings, and identify the determinants of persistence among RA patients initiating treatment with an SC-TNFi. Methods: The French national health insurance scheme database lists all outpatient and inpatient healthcare consumption for individuals covered by the general health insurance scheme. Using French claims data, RA was diagnosed using Long Term Disease status and hospital admission, based on ICD-10 codes. Patients were then identified through prescription filled for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM) between 2012/07/01 and 2013/12/31. A patient was considered as non-persistent in the event of a prolonged interruption of the therapy lasting 91 days or more. Persistence was estimated with Kaplan Meier analysis. Determinants of persistence in the 12 months before initiation were identified using Cox models. Results: A total of 7,204 patients with RA were identified. In the descriptive analyses of the 12 months persistence, differences were observed for RA patients, with raw/non-adjusted persistence rates of 51.8% for CZP, 57.4% for ETA, 53.7% for ADA and 56.6% for GLM. Results of the Cox model are presented below, including hazard ratio for biotherapy, adjusted on sex, age, socio-economic status, and criteria on disease severity. The variables biotherapy, sex and socio-economic status did not meet the proportionality hypothesis of risks, and were corrected by the addition of a variable integrating the interaction with time.
Background: Biotherapies such as subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFis) have transformed the management of inflammatory joint diseases such as psoriatic arthritis (PsA). The assessment of SC-TNFis persistence and its determinants is needed. Objectives: The objective of this study was to describe treatment persistence in real-world settings, and identify the determinants of persistence among PsA patients initiating treatment with an SC-TNFi. Methods: The French national health insurance scheme database lists all outpatient and inpatient healthcare consumption for individuals covered by the general health insurance scheme. Using French claims data, PsA was diagnosed using Long Term Disease status and hospital admission, based on ICD-10 codes. Patients were then identified through prescription filled for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM) between 2012/07/01 and 2013/12/31. A patient was considered as non-persistent in the event of a prolonged interruption of the therapy lasting 91 days or more. Persistence was estimated with Kaplan Meier analysis. Determinants of persistence in the 12 months before initiation were identified using Cox models. Results: A total of 2,011 patients with PsA were identified. In the descriptive analyses of the 12 months persistence, differences were observed for PsA patients, with raw/non-adjusted persistence rates of 37.3% for CZP, 51.8% for ETA, 54.7% for ADA and 50.8% for GLM. Results of the Cox model are presented, including hazard ratio for biotherapy, adjusted on sex, age, socio-economic status, and criteria on disease severity. The variables biotherapy, biotherapy line, comorbid conditions and hospital admission for IRMD did not meet the proportionality hypothesis of risks, and were corrected by the addition of a variable integrating the interaction with time. Background: Patients (pts) with RA have increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Treatment with tofacitinib may increase total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c) and high-density lipoprotein-cholesterol (HDL-c), without affecting TC/HDL-c ratio. Objectives: To evaluate major adverse CV event (MACE) risk factors in tofacitinibtreated pts with RA in the clinical development programme. Methods: Data were pooled from pts with moderately to severely active RA receiving ≥1 tofacitinib dose in 6 Phase 3 and 2 long-term extension (LTE) studies (1 LTE study ongoing, data cut-off: April 2015). MACE was any MI, stroke or CV death (coronary, cerebrovascular, cardiac (Table) . BL disease activity and inflammation measures were not associated with MACE risk (Table) . In multivariate analysis, BL age, hypertension and the TC/HDL-c ratio were significantly associated with MACE risk. Increases in HDL-c (p<0.001) and decreases in TC/HDL-c ratio (p<0.05) after 24 wks of tofacitinib therapy were significantly associated with decreased risk of future MACE (Figure) . Increases in erythrocyte sedimentation rate (ESR; p=0.09) may be associated with increased future MACE risk. Changes in TC, LDL-c or other disease activity measures were not associated with future MACE risk.
Conclusions:
In pooled analyses of tofacitinib-treated pts (age and BL value adjusted), increases in LDL-c and TC after 24 wks of tofacitinib therapy were not associated with future MACE risk. Increases in HDL-c and decreases in the TC/HDL-c ratio after 24 wks of tofacitinib therapy were associated with reduced future MACE risk. Increases in ESR after 24 wks may be associated with increased future MACE risk. More data are needed to confirm these findings.
